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experience. Overall, no signiﬁcant differences in infarct size or myocardial recovery were
demonstrated between PICSO-treated and matched control patients. However, infarct size
reduction from 2-5 days to 4-months was greater for patients treated with high (>median)
PICSOquantity, compared to those treatedwith lowPICSOquantity (less than themedian)
(41.68.2% vs 21.114.1%, p¼0.02), and also compared to their matched controls
(41.68.2% vs 27.79.9%, p¼0.04).
Conclusions: PICSO is safe after pPCI for STEMI, although feasibility was limited
and depended on center experience. Administration of high PICSO quantity was
associated with enhanced infarct size reduction, suggesting a dose-effect relationship
of PICSO on myocardial recovery.
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Background: Everolimus-eluting stent (EES) is associated with a lower rate of stent
thrombosis even in the setting of ST elevation myocardial infarction (STEMI). The aim
of this study was to compare vessel responses at 3 and 6 weeks follow-up after EES or
BMS implantation using optical coherence tomography (OCT) in STEMI patient.
Methods: We recruited patients with STEMI requiring emergent PCI and who received
EES or BMS from May 2010 to February 2014. A total of 20 STEMI patients with de
novo native coronary lesions were enrolled in this study. Ten EES and 10 BMS were
implanted in STEMI patients. All patients received dual-antiplatelet therapy (clopidogrel
75 mg/day and aspirin 100 mg/day). OCT examination was performed at 3 and 6 weeks
follow-up after EESorBMS implantation.Cross-sectional area (CSA)were analyzed at 1
mm intervals. The well-apposed coverage (covered struts/ total struts  100) were
evaluated byOCT.Mean neointimal hyperplasia (NIH) thickness and%NIH ((stent area
– lumen area)/stent area  100) were also measured. The percentage of thrombi were
calculated as the (number of CSA with thrombus/total number of CSA)  100.
Results: The well-apposed coverage at 3 weeks was 87.8% with EES, 89.0% with
BMS (p¼0.78), and at 6 weeks was 96.0% with EES, 94.7% with BMS (p¼0.72). %
NIH and mean NIH thickness were signiﬁcantly lower with EES compared with BMS
at both weeks. % thrombi was signiﬁcantly lower with EES compared with BMS at 3
weeks (11.2% vs 42.6%, p< 0.01), but was similar to EES and BMS at 6 weeks (6.1%
vs 7.6%, p¼0.68). The data are shown in Table.
Conclusions: Neointimal coverage of EES was similar to BMS at 3 and 6 weeks after
implantation. However, the incidence of thrombus was signiﬁcantly lower in EES at 3
weeks, which may explain low rate of acute and subacute stent thrombosis of EES as
compared with BMS.3 weeks 6 weeks
EES BMS p EES BMS p
No. of patients (n) 5 5 5 5
Stent diameter (mm) 3.00.2 3.30.6 0.49 2.90.5 3.00.2 0.68
Stent length (mm) 40.221.2 19.05.2 <0.05 36.016.0 21.45.9 0.09
No. of stent struts (n) 366.0229.9 181.650.5 0.118 312.0159.6 284.4118.8 0.76
OCT ﬁndings
Malapposed (%) 7.66.5 12.319.8 0.63 7.35.1 0.00.0 <0.05
Well-apposed coverage
(%)
87.84.6 89.08.1 0.78 96.04.0 94.76.3 0.72
% NIH (%) 3.80.4 5.71.3 <0.05 5.01.1 15.59.4 <0.05
Mean Thickness (mm) 61.87.1 87.823.1 <0.05 66.011.6 213.9116.6 <0.05
% thrombi (%) 11.28.0 42.618.7 <0.01 6.15.1 7.65.6 0.68
No. of total CSA (n) 186 95 180 105
No. of CSA with thrombi
(n)
15 38 11 8TCT-22
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Background: Residual intrastent thrombus is readily assessed after stenting in pri-
mary percutaneous coronary intervention (PPCI), with variable level of accuracy.
Uncertain though is association of residual intrastent thrombus on prognosis and/or
left ventricular ejection fraction (LVEF). Aim of the study was to evaluate semi-
quantitatively the relation between residual intrastent thrombus as assessed by fre-
quency domain OCT (FD-OCT) after PPCI, with LVEF at discharge.
Methods: From dicember 2012 to dicember 2013, 112 consecutive patients, treated
with PPCI, were studied. Overall underwent FD-OCT after stenting. The amount of
residual intrastent thrombus was calculated as stent area minus lumen area; the % ofJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acintrastent thrombus area (%ThA) was calculated as thrombus area/stent area. Patients
were divided on the basis of reduced (50%) or preserved (>50%) LVEF calculated
by echocardiography at discharge. Clinical follow-up was completed for all at 1,3,6,12
months by phone interview.
Results: After PPCI, mean LVEF in all patients was 53.639.6%. LVEF>50% was
observed in 61% (69/112) of the patients, while LVEF 50% 39% (43/112). After the
procedure, overall %ThA was 4.7  1.3. Patients with preserved LVEF >50% had
signiﬁcantly less %ThA than patients with LVEF 50% (4.31.8 vs 5.34.6;
p¼0.05). MACE were observed in 9/112 patients. Patients with MACE had higher
values of %ThA than patients without MACE (6.02.5 vs 4.51.3; p¼0.09).
Conclusions: In STEMI patients treated with PPCI, LVEF 50% seems to be asso-
ciated with more %ThA than LVEF>50%. MACE are associated with higher values of
%ThA. Residual intrastent thrombus can be a negative prognostic marker in STEMI.
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Background: The frequency, causes, and impact of myocardial infarction (MI) after
successful percutaneous coronary intervention (PCI) have not been well-studied.
Methods: ADAPT-DES was a prospective, multicenter, “all-comers” study of PCI with
drug-eluting stents (DES) in 8582 pts at 11 centers in the US andGermany.After excluding
125 pts with periprocedural MI, we investigated the etiology, frequency, and long-term
consequences of post-proceduralMI after successful and uncomplicatedDES implantation.
Results: Of 8457 pts without peri-procedural MI, post-procedural MI developed
during 2-year follow-up in 263 pts (3.1%). The median [IQR] time to post-procedural
MI was 318 [129, 503] days. Post-procedural MIs were attributable to: (1) non-target
lesion-related spontaneous MI (78 pts [29.7%]); (2) secondary (supply/demand
imbalance) or indeterminate MI (64 pts [24.3%]); (3) stent thrombosis (ST) related MI
(63 pts [24.0%]); and (4) in-stent restenosis (ISR) related MI (58 pts [22.1%]). Pts who
experienced a post-procedural MI had signiﬁcantly greater 2-year mortality than those
without MI (17.3% vs 3.4%, P< 0.001). The impact of post-procedural MI according
to etiology appears in the Figure. After adjustment for important clinical covariates,
the occurrence of post-procedural MI was associated with a 6.7-fold higher risk of
death at 2 years (95% CI 4.8 to 9.4, p< 0.001).Conclusions: Post-procedural MI within 2 years of successful DES implantation is
relatively infrequent but has numerous etiologies and is a strong independent predictor
of subsequent mortality.ute Myocardial Infarction B7
